external image 6849.jpg

General Information

Company Name
Year founded
Key People
Professor Jan Lubiński – Chief Executive Officer
151 154 €
Net Income
252 533 € (for 2009)

READ-GENE SA is a pioneering venture in the Polish market. It is first biotechnological polish company of innovative technologies, which aim is to commercialize methods of detection, prevention and treatment of the most common types of malignant tumours. The company’s special fields are chemoprevention, clinical trials and genetic testing, all complementary fields.


12 5
  • 13 VI 2005 - The year the company was founded.
  • VI 2006 - use cis-platin therapy in BRCA1-positive breast cancer patients
  • XII 2008 - launch an Internet platform on which you can order tests for the detection of gene mutation BRCA1, BRCA2, MSH2, MLH1, NBS1 and CHEK2
  • 12 II 2009 - debut of the shares on the Stock Exchange in Warsaw
  • 17 III 2010 - record company's share price READ-GENE NewConnect exchange, share price rose by 288.89%
  • IV-XII 2010 - construction of a new R & D center of genetic studies of cancer, application *has been approved by the Ministry of Economy to support the Operational Programme Innovative Economy
  • 2010 - marketing of functional foods (selenium& anti selenium, water enriched with oxygen,anti supplements)

Company employees are scientists from the International Hereditary Cancer Center and Department of Genetics and Pathology, operating under the Pomeranian Medical University in Szczecin. The main goal of the operation of IHCC is to create scientific solutions that can be used in practice, prevention, diagnosis, matching the most appropriate method of prevention against cancer and to treatment of cancer.


Read-Gene has unique patent portfolio for DNA testing and chemopreventive pharmaceuticals:
a) 5 international patents granted ( 3 in USA, 1 in Euroasia, 1 in RPA)
b) 6 Polish patents granted
c) submission of ten Polish and international patent applications for its genetic cancer discoveries


Currently, READ-GENE has got database of genetic samples, which contains nearly 2 million data and more than 185 thousand DNA samples. Among these data there are over 4 200 diagnosed and registered in BRCA1 mutation carriers and more than 21 000 CHK2 mutation carriers, ie, NOD2, CDKN2A, CYP1B1, NBS1, p53, FGFR, TNR


  • 1. Test of significantly decreased risk of breast cancer - This test detects women without any of genetic changes associated with increased risk of breast cancer (high or moderate) identified in the Polish/Slavic population.
  • 2. Test of moderately increased risk of malignancies of various sites - This test detects 28 mutations/polymorphisms in the following genes: BRCA2, XPD, MC1R, VDR, CYP1B1, p53, NOD2,CHEK2, FGFR2, MAP3K, TNRC9, CDKN2A, MTHFR, ATM and NBS1.
  • 3. Test detecting inclusion criteria to clinical trial of Trabectedin treatment for patients with breast cancer with BRCA1 mutation -
  • 4. Test detecting inclusion criteria to clinical trial of cis-platin treatment for patients with cancers at various sites - It seems justified that patients with BRCA1 constitutional mutation will consider to participate in clinical trial of malignancies treatment with cis-platinum.
  • 5. Test detecting inclusion criteria to clinical trial of "Inhibitor PARP" treatment for patients with ovarian cancer with BRCA1 mutation-
  • 6. Prostate Cancer High-Risk Test - This test detects carriers of 7 specific mutations in BRCA1, NBS1 and CHEK2 genes.
  • 7. Colon Cancer High-Risk Test -This test detects carriers of MSH2, MSH6, MLH1 and APC mutations. All of 47 examined changes have been identified as recurrent and characteristic for Polish/ Slavic populations and can cause high risk of colorectal cancer.
  • 8. Breast Cancer High-Risk Test – Polygenic-Offered test detects 7 changes in CHEK2, CYP1B1 and BRCA2 genes which are associated with high (RR ~ 5) risk of 40 years if they are accumulated in one female in appropriate combinations.
  • 9. Breast Cancer High-Risk Test - Monogenic -Inherited mutation in BRCA1 and BRCA2 genes are associated with high risk of breast and/or overian cancer. Offered test detects 21 recurrent mutations occurring in BRCA1 and BRCA2 genes.

all of this test you can order by the Internet



Anna Bot, n°68789; MBiotec

  1. bioinformatics
  2. biopharmaceutical
  3. company
  4. genetic tests
  5. monoclonal antibodies
  6. nanobiotechnology
  7. penicillin; antibiotics
  8. pharmaceutical
  9. poland
  10. portugal
  11. product
  12. technology
  13. tool
  14. vaccine